Pravastatin belongs to HMG-CoA reductase inhibitor, in contrast to placebo, pravastatin utilization cuts down the concentration of low-density lipoprotein cholesterol and minimizes nonfatal myocardial infarction risk and coronary heart disease mortality [55]. This evidence concerns the gene HMGCR and myocardial infarction.